It is our pleasure that we are able to participate and witness the success of New Horizon Health (6606.HK) to become an industry creditable leader. NHH’s IPO price skyrocketed from HKD 26.66 per share to a remarkable closing price at HKD 84.0 per share on 18 Feb, with 215% increment. We are so honored to lead NHH’s Series C round financing in 2019 which was actually our first leading Healthcare investment. We continued to invest in the Company’s subsequent Series D round of financing in 2020.

VMS has been focusing on Healthcare investment since 2017, leading by Andrew Ng, Managing Director and Head of Healthcare of VMS Asset Management. We comprise hybrid vigor and expertise on Healthcare sectors, exploring an intrinsic value for distinctive investments within the sector. The investments in portfolio companies NHH, KingMed (603882.CH), Pharmaron (300759.CH), i-Mab (IMAB.US), CareRay (688607.CH) and Gamida Cell (GMDA.US) have already proven our commitment and we believe this diversity will seize more investment landscapes for our investors.

We are very looking forward in 2021 with anticipation a strong growth on our invested portfolio companies Zhaoke and Kemei (CHIVD) in upcoming IPOs at Hong Kong and Shanghai Star Board.

If you would like to hear the latest updates on the Firm and the Fund, please feel free to contact our Investor Relations team at IR@VMSIG.COM.